

A combination of MTP inhibitors and HMG-CoA reductase inhibitors and the use thereof in medicaments

Abstract

The invention relates to the use of a combination of at least one selected MTP inhibitor (component A) and an HMG-CoA reductase inhibitor (component B) for the control of cardiovascular diseases, to medicaments comprising this combination and to their production.

10019007-122101